<DOC>
	<DOCNO>NCT02792062</DOCNO>
	<brief_summary>The purpose study evaluate food effect pharmacokinetics single oral dose TAK-385 Japanese premenopausal healthy adult woman .</brief_summary>
	<brief_title>A Phase 1 , Food Effect Study TAK-385 Final Formulation</brief_title>
	<detailed_description>This phase 1 clinical pharmacological study TAK-385 Japanese premenopausal healthy adult woman . Using open-label 3Ã—3 crossover design , food effect pharmacokinetics safety TAK-385 evaluate participant receive single oral dose TAK-385 40 mg fast condition without breakfast , breakfast , breakfast . Participants determine eligible randomly assign one Groups A F prior study medication administration Period 1 ; subsequently , participant receive one TAK-385 40 mg tablet fast condition without breakfast ( follow minimum 10-hour overnight fast ) , breakfast ( 30 minute start breakfast ) , breakfast ( 30 minute start breakfast ) Periods 1 , 2 , 3 .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form prior initiation study procedure . 3 . The participant Japanese premenopausal healthy adult woman . 4 . The participant age 20 45 year , inclusive , time informed consent . 5 . The participant weighs least 40.0 kg body mass index ( BMI ) 18.5 25.0 kg/m2 , inclusive Screening . 6 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception throughout duration study , time signing informed consent form . 7 . The participant experience 3 consecutive regular menstrual cycle prior time inform consent . 1 . The participant receive investigational drug within 16 week ( 112 day ) prior first dose study medication Period 1 . 2 . The participant receive TAK385 previous clinical study . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The participant uncontrolled , clinically significant neurological , circulatory , pulmonary , hepatic , renal , metabolic , gastrointestinal , urinary , endocrine disease , abnormality , may impact ability participant participate study potentially confound study result . 5 . The participant diagnosis abnormal menstruation . 6 . The participant undiagnosable abnormal genital bleeding . 7 . The participant know hypersensitivity allergy drug . 8 . The participant positive urine drug test result drug abuse positive breath alcohol test result Screening . 9 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior screen unwilling agree abstain alcohol drug throughout study period . 10 . The participant take excluded medication , vitamin supplement , food product list Excluded Medications Dietary Products table . 11 . The participant use oral contraceptive sex hormone preparation ( norethindrone , norethisterone , medroxyprogesterone , estrogen , progestin ) within 8 week ( 56 day ) prior hospitalization Period 1 ( Day 1 ) , gonadotropinreleasing hormone ( GnRH ) analogue , dienogest , danazol , aromatase inhibitor within 16 week ( 112 day ) prior hospitalization Period 1 ( Day 1 ) [ within 20 week ( 140 day ) 28 week ( 196 day ) prior hospitalization 1 3month sustained preparation , respectively ] . 12 . The participant pregnant lactate intend become pregnant time inform consent , study , within 1 month complete study ; intend donate ova time period . 13 . The participant evidence current cardiovascular disease , central nervous system disease , hepatic disease , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma , hypoxemia , hypertension , thromboembolism , seizure , allergic skin rash , gastrointestinal disease ( pseudomembranous colitis ) , mental disorder ( especially depressionlike symptom ) resultant suicide attempt . The participant medical history , physical examination finding , safety laboratory test find reasonably indicative disease would contraindicate GnRH analogue , may interfere conduct study . This include peptic ulcer disease , seizure disorder , cardiac arrhythmia . 14 . The participant current recent ( within 6 month ) gastrointestinal disease may influence absorption drug ( ie , malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent heartburn , surgical intervention ) . 15 . The participant history cancer . 16 . The participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antigen/antibody , serological reaction syphilis Screening . 17 . The participant use nicotinecontaining product ( cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum , etc . ) within 28 day prior hospitalization Period 1 ( Day 1 ) , unwilling agree stop use product throughout study . 18 . The participant poor peripheral venous access . 19 . The participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 16 week ( 112 day ) prior start study medication administration Period 1 . 20 . The participant undergone whole blood collection least 400 mL total within 52 week ( 364 day ) prior start study medication administration Period 1 . 21 . The participant undergone blood component collection within 2 week ( 14 day ) prior start study medication administration Period 1 . 22 . The participant clinically significant abnormal electrocardiogram ( ECG ) Screening prior study medication administration Period 1 . 23 . The participant abnormal laboratory value suggest clinically significant underlying disease ALT and/or AST &gt; 1.5 upper limit normal Screening prior study medication administration Period 1 . 24 . The participant , opinion investigator subinvestigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>